The goal of the study was to evaluate the therapeutic efficacy of the Monoclonal anti-CD20 Antibody Rituximab and the increase of chemotherapy cycles from 6 to 8.

RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.

Investigation position:

help Creators and Submitter

Views: 4315

Created: 16th May 2019 at 14:02

Last updated: 20th May 2019 at 11:49

Powered by
Copyright © 2008 - 2021 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig

By continuing to use this site you agree to the use of cookies